Search results for "steroids"

showing 10 items of 203 documents

How to treat tumefactive demyelinating disease?

2013

Glioma-like inflammatory demyelinating lesions can be found in patients with pre-diagnosed multiple sclerosis, but they have also been described as an isolated disease entity. The initial diagnostic work-up usually includes a biopsy for histopathological analysis. However, even after unambiguous histopathologic classification, tumefactive lesions pose a therapeutic challenge. Until now, there have been no guidelines on how to treat patients with these rare and extreme lesion phenotypes. Here we report a patient with a relapsing unifocal tumefactive demyelinating lesion. The patient initially showed a good response to steroid treatment, with full clinical recovery. However, after relapse of…

Malemedicine.medical_specialtyPathologyTime FactorsBiopsymedicine.medical_treatmentDrug Administration ScheduleLesionRecurrenceInduction therapyBiopsymedicineDemyelinating diseaseHumansIn patientmedicine.diagnostic_testDrug Substitutionbusiness.industryMultiple sclerosisImmunosuppressionMiddle Agedmedicine.diseaseMagnetic Resonance ImagingRegimenTreatment OutcomeNeurologyDrug Therapy CombinationSteroidsNeurology (clinical)Radiologymedicine.symptombusinessImmunosuppressive AgentsDemyelinating DiseasesMultiple Sclerosis Journal
researchProduct

Involvement of secretory phospholipase A2 activity in the zymosan rat air pouch model of inflammation.

1996

1. In the zymosan rat air pouch model of inflammation we have assessed the time dependence of phospholipase A2 (PLA2) accumulation in the inflammatory exudates as well as cell migration, myeloperoxidase activity, prostaglandin E2 (PGE2) and leukotriene B4 (LTB4) levels. 2. A significant increase in PLA2 activity was detected in 1,200 g supernatants of exudates 8 h after injection of zymosan into rat air pouch. This event coincided with peaks in cell accumulation (mainly neutrophils) and myeloperoxidase activity in exudates and was preceded by a rise in eicosanoid levels. 3. This enzyme (without further purification) behaved as a secretory type II PLA2 with an optimum pH at 7-8 units, lack o…

Malemedicine.medical_specialtySesterterpenesLeukotriene B4NeutrophilsAnti-Inflammatory AgentsLeukotriene B4DinoprostonePhospholipases AManoalidechemistry.chemical_compoundPhospholipase A2Internal medicinemedicineAnimalsProstaglandin E2Rats WistarPeroxidasePharmacologyInflammationAnalysis of VariancebiologyTerpenesZymosanZymosanRatsPhospholipases A2EndocrinologyEicosanoidBiochemistrychemistryMyeloperoxidasebiology.proteinHomosteroidslipids (amino acids peptides and proteins)PouchColchicinemedicine.drugResearch ArticleBritish journal of pharmacology
researchProduct

Model‐based meta‐analysis of the time to first acute urinary retention or benign prostatic hyperplasia‐related surgery in patients with moderate or s…

2021

Aims Combination therapy of 5α‐reductase inhibitor and α‐blocker is a guideline‐endorsed therapeutic approach for patients with moderate‐to‐severe lower urinary tract symptoms or benign prostatic hyperplasia (LUTS/BPH) who are at risk of disease progression. We aimed to disentangle the contribution of clinical and demographic baseline characteristics affecting the risk of acute urinary retention or BPH‐related surgery (AUR/S) from the effect of treatment with drugs showing symptomatic and disease‐modifying properties. Methods A time‐to‐event model was developed using pooled data from patients (n = 10 238) enrolled into six clinical studies receiving placebo, tamsulosin, dutasteride or tamsu…

Malemedicine.medical_specialtydisease‐modifying propertiesCombination therapyProstatic HyperplasiaPlacebo030226 pharmacology & pharmacy03 medical and health scienceschemistry.chemical_compound0302 clinical medicinebaseline risk factorsLower urinary tract symptomsTamsulosinHumansMedicinePharmacology (medical)lower urinary tract symptoms030212 general & internal medicineacute urinary retentionPharmacologybenign prostatic hyperplasiadutasterideSulfonamidesbusiness.industryUrinary retentionHazard ratioOriginal ArticlesUrinary Retentionmedicine.diseaseDutasterideSurgeryTreatment OutcomechemistryAzasteroidstamsulosinOriginal ArticleDrug Therapy CombinationInternational Prostate Symptom Scoremedicine.symptombusinesstime‐to‐event modellingmedicine.drugBritish Journal of Clinical Pharmacology
researchProduct

Insight into the molecular sex dimorphism of ischaemic stroke in rat cerebral cortex: Focus on neuroglobin, sex steroids and autophagy

2020

Including sex is of paramount importance in preclinical and clinical stroke researches, and molecular studies dealing in depth with sex differences in stroke pathophysiology are needed. To gain insight into the molecular sex dimorphism of ischaemic stroke in rat cerebral cortex, male and female adult rats were subjected to transient middle cerebral artery occlusion. The expression of neuroglobin (Ngb) and other functionally related molecules involved in sex steroid signalling (oestrogen and androgen receptors), steroidogenesis (StAR, TSPO and aromatase) and autophagic activity (LC3B-II/LC3B-I ratio, UCP2 and HIF-1 alpha) was assessed in the ipsilateral ischaemic and contralateral non-ischae…

Malemedicine.medical_specialtysteroidogenesisNeuroprotectionBrain IschemiaRats Sprague-Dawley03 medical and health sciences0302 clinical medicineInternal medicineCortex (anatomy)sex steroid signallingmedicineAutophagyAnimalssex dimorphismAromataseStroke030304 developmental biologyIschemic StrokeCerebral Cortex0303 health sciencesSex Characteristicsischaemic strokebiologybusiness.industryGeneral NeuroscienceInfarction Middle Cerebral Arterymedicine.diseaseRatsAndrogen receptorStrokeDisease Models AnimalneuroglobinEndocrinologymedicine.anatomical_structureSex steroidCerebral cortexNeuroglobinbiology.proteinFemaleSteroidsbusiness030217 neurology & neurosurgery
researchProduct

Tocilizumab as first treatment option in optic neuropathy secondary to Graves' orbitopathy.

2018

Dysthyroid optic neuropathy (DON) is one of the complications that can affect Graves' orbitopathy (GO) patients. Its prevalence is estimated at less than 5%. It is usually treated with intravenous steroids, radiotherapy or orbital decompression. Tocilizumab has been proposed as a treatment option in cases of GO refractory to steroid treatment, with good clinical results. Our aim is to report the case of a patient with optic neuropathy secondary to GO treated with tocilizumab as primary treatment option.

Malemusculoskeletal diseasesDecompressionmedicine.medical_specialtyDecompressionmedicine.medical_treatmentVisual Acuity030209 endocrinology & metabolismdysthyroid optic neuropathyAntibodies Monoclonal HumanizedOptic neuropathy03 medical and health scienceschemistry.chemical_compoundGraves' orbitopathytocilizumab0302 clinical medicineTocilizumabRefractoryOptic Nerve DiseasesmedicineHumansbusiness.industryTreatment optionsMiddle Agedmedicine.diseaseeye diseasesSurgeryRadiation therapyGraves OphthalmopathyOphthalmologychemistry030221 ophthalmology & optometryPrimary treatmentVisual FieldsIntravenous steroidsbusinessTomography Optical Coherencesteroids
researchProduct

Tocilizumab induces corticosteroid sparing in rheumatoid arthritis patients in clinical practice

2015

International audience; Objective. The aim of this study was to evaluate the impact of introducing tocilizumab (TCZ) as co-therapy with CS in patients with RA.Methods. This study was an open, observational, retrospective multicentre study. RA patients treated with oral CS for >3 months who started treatment with TCZ between December 2009 and June 2011 in five centres were included. Variables included demographic data, disease history, co-treatments, disease activity and dose of CS at inclusion and at weeks 4, 8, 12 and 24. The evolution of disease activity and of the dose of CS (analysis of variance with repeated measures) were analysed, searching for factors correlated with changes in the …

Malerheumatoid arthritisGastroenterologycorticosteroidsArthritis Rheumatoidchemistry.chemical_compoundPrednisoneAdrenal Cortex HormonesPharmacology (medical)risksystemic glucocorticoid therapytreatmentfactor-alpha inhibitorsMiddle Aged3. Good healthClinical PracticeTreatment Outcome[SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal systemRheumatoid arthritisAntirheumatic AgentsCorticosteroidDrug Therapy CombinationFemaleAnalysis of variancemanagementmedicine.drugAdultmedicine.medical_specialtymedicine.drug_classAntibodies Monoclonal Humanizeddiseases[ SDV.MHEP.RSOA ] Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal systemtocilizumabTocilizumabRheumatology[SDV.SP.MED]Life Sciences [q-bio]/Pharmaceutical sciences/MedicationInternal medicinemedicineHumansIn patientbiologicsGlucocorticoidsAgedRetrospective Studiesbusiness.industry[ SDV.SP.MED ] Life Sciences [q-bio]/Pharmaceutical sciences/MedicationRepeated measures designeular recommendationsmedicine.diseaseEndocrinologychemistryPrednisonebusiness
researchProduct

An all-organic steroid–D–π-A modular design drives ferroelectricity in supramolecular solids and nano-architectures at RT

2011

Confluence of a modular design approach and self-assembly with a 'steroid-D-π-A' module generates spontaneous polarization in solids and for the first time in nano-architectures constituted from organogels, at room temperature (RT).

Materials sciencebusiness.industryMolecular ConformationTemperatureMetals and AlloysSupramolecular chemistryNanotechnologyGeneral ChemistryModular designCrystallography X-RayFerroelectricityCatalysisNanostructuresSurfaces Coatings and FilmsElectronic Optical and Magnetic MaterialsSpontaneous polarizationElectricityNano-Materials ChemistryCeramics and CompositesSteroidsbusinessta116Chemical Communications
researchProduct

Non-Skeletal Activities of Vitamin D: From Physiology to Brain Pathology.

2019

Vitamin D is a secosteroid hormone regulating the expression of almost 900 genes, and it is involved in the regulation of calcium and phosphate metabolism, immune response, and brain development. Low blood vitamin D levels have been reported in patients affected by various diseases. Despite a large amount of literature data, there is uncertainty surrounding the role of vitamin D as a serum biomarker in Alzheimer’s disease (AD) and Parkinson’s disease (PD). Indeed, the lack of internationally recognized 25(OH)D3 reference measurement procedures and standard materials in the past led to unstandardized serum total 25(OH)D3 results among research and clinical care laboratories. Thus…

Medicine (General)Parkinson's diseasePhysiologyvitamin DDiseaseReviewSecosteroidbrain functionchemistry.chemical_compound25(OH)D3R5-920Immune systemAlzheimer DiseaseVitamin D and neurologyMedicineHumansSecosteroidsBrain functionbusiness.industryParkinson DiseaseGeneral Medicinemedicine.diseaseVitamin D Deficiencyimmune system25(OH)D<sub>3</sub>chemistryParkinson’s diseaseBiomarker (medicine)businessAlzheimer’s diseaseBiomarkersHormoneMedicina (Kaunas, Lithuania)
researchProduct

Microscopic Study of Injectable Steroids: Effects of Postmixing Time on Particle Aggregation

2020

Background: Epidural steroid injection (ESI) is a common practice for pain treatment since 1953. In 2014, the FDA issued a warning about ESI. Studies have focused on the effect of the particle size and their ability to generate harmful aggregates. Although steroid aggregates provide longer times for reabsorption, therefore a longer anti-inflammatory effect, they are potentially harmful to the central nervous system via embolic mechanisms. Previous studies have established that steroidal aggregates with asizes over 100 μm are potentially able to occlude blood vessels. Studies by Tiso et al and Benzon et al addressed the role of steroids on CNS adverse events, with similar outcomes. The main …

MicroscopyR softwareTriamcinolone acetonidebusiness.industryEpidural steroid injectionmedicine.medical_treatmentInjections EpiduralPharmacologyTriamcinoloneBetamethasoneDexamethasoneSteroidParticle aggregationAnesthesiology and Pain MedicineHumansMedicineBetamethasoneSteroidsParticle sizeParticle SizebusinessGlucocorticoidsDexamethasonemedicine.drugPain Physician
researchProduct

Steroidal glycosides from Ornithogalum dubium Houtt

2018

The phytochemical study of Ornithogalum dubium Houtt. (Asparagaceae) led to the isolation of five undescribed steroidal glycosides together with two known ones. Their structures were established by using NMR analysis and mass spectrometry as (25R)-3β-hydroxyspirost-5-en-1β-yl O-α-L-arabinopyranosyl-(1 → 2)-α-L-rhamnopyranoside, (25S)-3β-hydroxyspirost-5-en-1β-yl O-β-D-glucopyranosyl-(1 → 6)-β-D-glucopyranoside, (22S)-16β-[(α-L-rhamnopyranosyl)oxy]-22-hydroxycholest-5-en-3β-yl O-β-D-glucopyranosyl-(1 → 4)-β-D-glucopyranoside, (22S,23S)-1β,3β,11α,16β,23-pentahydroxy-5α-cholest-24-en-22β-yl β-D-glucopyranoside, (22S,23S)-3β-[(β-D-glucopyranosyl)oxy]-22,23-dihydroxy-5α-cholest-24-en-16β-yl O-α-…

Models Molecular0106 biological sciencesSteroidal glycosidesStereochemistryAntineoplastic AgentsHL-60 CellsPlant ScienceHorticulture01 natural sciencesBiochemistryAsparagaceaeCarbohydrate ConformationmedicineHumansCytotoxic T cellGlycosidesCytotoxicityMolecular BiologyCisplatinOrnithogalum dubiumbiology010405 organic chemistryChemistryGeneral Medicinebiology.organism_classificationmedicine.disease0104 chemical sciencesLeukemiaPhytochemicalA549 CellsOrnithogalumSteroids010606 plant biology & botanymedicine.drugPhytochemistry
researchProduct